Illustrative estimate only - not verified by this sponsor. Contact the study team for actual compensation.
The purpose of this protocol is to determine the effect of two clinically applicable Dexmedetomidine dosages (0.5mcg/kg and 1mcg/kg) on the minimum alveolar concentration (MAC) of Sevoflurane in children between the age ranges of: 1-6 months; 6-12 months of age and 12 months-36 months years of age.
What happens when you apply
Reach out via phone or email to express interest
Brief call to discuss your health history
Medical screening at the research site
Begin your journey in the study
Exclusion Criteria: 1. Interstitial lung disease, chest wall disease, or bronchospastic disease with no flare-ups in the past 2 weeks of presentation 2. History of difficult intubation or ventilation 3. Airway malformation 4. Congenital heart disease 5. Cardiac arrhythmias 6. Central nervous system disease, including developmental delay, cerebral palsy, or seizure disorder 7. History of or family history of malignant hyperthermia 8. Electrolyte disorders 9. Gastrointestinal disease 10. Hepatic dysfunction 11. Renal dysfunction 12. Metabolic disease, such as diabetes 13. Obesity, defined as a body mass index greater than the 95% percentile for age 14. Preterm infant (less than 37 weeks gestational age) 15. Use of any medications (anticonvulsants, opioids, benzodiazepines, antibiotics, antihistamines drugs that induce hepatic enzymes) that may affect MAC. Inclusion Criteria All patients age 1 month- 3 years presenting for surgery.
imaguineapig pulls live data from ClinicalTrials.gov (NIH/NLM).Illustrative estimate only - not verifiedPay estimates are approximate ranges based on study type and are not confirmed by sponsors — actual compensation may differ. Eligibility indicators use limited criteria (age, sex) only. We do not provide medical advice. Always contact the study team directly to confirm compensation, full eligibility, and risks before enrolling.